๐ Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Bliss GVS Pharma Announces TDS Guidelines for Re. 0.50 Interim Dividend; Record Date Feb 18
Bliss GVS Pharma has declared an interim dividend of Re. 0.50 per equity share for the financial year 2025-2026. The company has established February 18, 2026, as the record date to identify eligible shareholders for this payout. This communication outlines the Tax Deduction at Source (TDS) procedures, where a 10% tax will be deducted for resident shareholders with a valid PAN. Shareholders must submit necessary tax exemption forms like 15G/15H by February 23, 2026, to avoid higher tax withholding.
Key Highlights
Interim dividend of Re. 0.50 per equity share (50% of face value) declared for FY 2025-26.
Record date for dividend eligibility is fixed as Wednesday, February 18, 2026.
TDS of 10% applies to resident shareholders with PAN; 20% applies if PAN is invalid or not linked to Aadhaar.
No TDS for resident individuals if the total dividend received during FY 2025-26 does not exceed Rs. 10,000.
Deadline for submitting tax-related documents (Form 15G/15H/TRC) is Monday, February 23, 2026.
๐ผ Action for Investors
Shareholders should ensure their PAN and Aadhaar are linked and bank details are updated in their demat accounts to receive the dividend smoothly. If eligible for tax exemption, submit Form 15G/15H to the company's registrar by the February 23 deadline.
Bliss GVS Pharma Clarifies Speculative News Regarding Stake Sale to Anupam Rasayan
Bliss GVS Pharma has officially addressed a news report from CNBC Awaaz dated February 13, 2026, which suggested that Anupam Rasayan might acquire a stake in the company. The company clarified that this news is speculative and did not originate from any official communication. As of the current date, no arrangement or decision regarding a stake sale has been finalized or approved by the promoters. The disclosure was made under Regulation 30(11) to prevent the establishment of false market sentiment.
Key Highlights
Company denies CNBC Awaaz report titled 'Bliss GVS เคฎเฅเค เคนเคฟเคธเฅเคธเคพ เคฒเฅ เคธเคเคคเฅ เคนเฅ เค
เคจเฅเคชเคฎ เคฐเคธเคพเคฏเคจ' as speculative.
Management confirms no decision or arrangement has been crystallized or approved by promoters as of Feb 13, 2026.
Clarification issued under SEBI Regulation 30(11) to maintain market integrity.
Investors advised to rely only on official exchange filings rather than media reports.
๐ผ Action for Investors
Investors should remain cautious and avoid reacting to unverified media reports, as the company has officially denied any finalized deal. Monitor the stock for volatility but prioritize official regulatory filings for investment decisions.
Bliss GVS Pharma: Two Whole-Time Directors Resign Effective February 10, 2026
Bliss GVS Pharma Limited has announced the resignation of two Whole-Time Directors, Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma, effective February 10, 2026. Both directors are daughters of the current Managing Director and CEO, Mr. Narsimha Shibroor Kamath, and cited other professional commitments as the reason for their departure. The Board accepted these resignations in a meeting held at shorter notice on the same day. This simultaneous exit of two family-member directors from the board marks a significant change in the company's executive leadership structure.
Key Highlights
Resignation of Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma as Whole-Time Directors effective Feb 10, 2026.
Both outgoing directors are daughters of the Managing Director & CEO, Mr. Narsimha Shibroor Kamath.
The resignations were attributed to other professional commitments by the directors.
The Board meeting to accept the resignations was held at shorter notice on February 10, 2026, between 5:30 PM and 6:00 PM.
Both individuals will also cease to be members of all company committees effective immediately.
๐ผ Action for Investors
Investors should monitor for any new board appointments to understand if the company is moving towards more professional management or if other family members will be inducted. The simultaneous exit of two promoter-related directors warrants a watch on the company's future succession and governance strategy.
Bliss GVS Pharma Declares 50% Interim Dividend; Sets Feb 18 as Record Date
Bliss GVS Pharma Limited has announced an interim dividend of โน0.50 per equity share for the financial year 2025-2026. This payout represents 50% of the face value of โน1 per share. The company has officially fixed Wednesday, February 18, 2026, as the record date to determine shareholder eligibility. The dividend is expected to be disbursed to eligible shareholders within 30 days of its declaration on February 10, 2026.
Key Highlights
Interim dividend of โน0.50 per equity share (50% of face value โน1) declared
Record date for dividend eligibility fixed as February 18, 2026
Dividend declared for the Financial Year 2025-2026
Payment to be completed within 30 days from the declaration date of February 10, 2026
๐ผ Action for Investors
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible for the โน0.50 per share payout. This announcement reflects a positive cash return to shareholders for the current fiscal year.
Bliss GVS Pharma Declares Interim Dividend of Rs 0.50 Per Share; Sets Record Date
Bliss GVS Pharma has declared an interim dividend of Rs 0.50 per equity share for the financial year 2025-26, which represents 50% of the face value of Re 1. The company has fixed February 18, 2026, as the record date to determine shareholder eligibility for this payout. This announcement was made alongside the approval of the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is scheduled to be paid to eligible shareholders within 30 days of its declaration.
Key Highlights
Interim dividend declared at Rs 0.50 per equity share (50% of face value)
Record date for dividend eligibility fixed as February 18, 2026
Dividend payment to be completed within 30 days from February 10, 2026
Approved unaudited standalone and consolidated financial results for Q3 FY26
๐ผ Action for Investors
Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to assess the company's operational performance.
Bliss GVS Pharma Approves Q3 FY26 Results; Declares 50% Interim Dividend
Bliss GVS Pharma Limited has approved its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In a positive move for shareholders, the Board declared an interim dividend of 50%, amounting to โน0.50 per equity share on a face value of โน1. The company has fixed February 18, 2026, as the record date for dividend eligibility. The dividend is scheduled to be paid within 30 days of the declaration.
Key Highlights
Approved unaudited standalone and consolidated financial results for Q3 and 9M FY2025-26.
Declared an interim dividend of 50%, which is โน0.50 per equity share of face value โน1.
Fixed Wednesday, February 18, 2026, as the record date for determining eligible shareholders.
Committed to paying the interim dividend within 30 days from the date of declaration.
๐ผ Action for Investors
Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. A detailed review of the full financial results is recommended to assess the company's underlying growth and margin performance.
Bliss GVS Pharma Declares โน0.50 Interim Dividend; Sets Feb 18 as Record Date
Bliss GVS Pharma has declared an interim dividend of โน0.50 per equity share for the financial year 2025-2026, representing a 50% payout on the face value of โน1. The Board has fixed February 18, 2026, as the record date to determine eligible shareholders for this payment. This announcement was made alongside the approval of the company's unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is mandated to be paid within 30 days of its declaration.
Key Highlights
Interim dividend of โน0.50 per equity share declared (50% of face value).
Record date for dividend eligibility set for February 18, 2026.
Dividend payment to be completed within 30 days from February 10, 2026.
Board approved unaudited financial results for Q3 and 9M ended December 31, 2025.
๐ผ Action for Investors
Investors looking to benefit from the dividend should ensure they hold the stock before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to evaluate the company's underlying earnings strength.
Bliss GVS Shareholders Approve Narsimha Kamath as Managing Director with 99.9% Majority
Bliss GVS Pharma Limited has announced the successful passage of a special resolution to appoint Mr. Narsimha Shibroor Kamath as Managing Director. The resolution was passed via postal ballot with an overwhelming majority of 99.90% of the votes cast in favour. A total of 6.37 crore votes were polled, representing approximately 60.21% of the total shareholding. The promoter group and public institutions showed unanimous support for the appointment, indicating strong internal and institutional alignment.
Key Highlights
Special resolution passed for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director
Total votes polled reached 6,36,93,053, representing 60.21% of the total 10.58 crore shares
The appointment received 99.90% approval (6,36,26,720 votes) from participating shareholders
Promoter group and Public Institutions voted 100% in favour of the resolution
Only 0.10% of votes (66,333) were cast against the proposal
๐ผ Action for Investors
Investors should view this as a positive sign of leadership continuity and strong shareholder backing. No immediate action is required, but monitoring the new MD's strategic direction for the company is advised.
Bliss GVS Pharma Proposes Appointment of Narsimha Shibroor Kamath as Managing Director
Bliss GVS Pharma has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director for a three-year term. Mr. Kamath, who currently serves as the Chief Executive Officer, will be redesignated as Managing Director & CEO upon approval. As he is 72 years old, the company is seeking a special resolution to confirm that his continued leadership is in the best interest of the firm. The e-voting process for shareholders will run from December 31, 2025, to January 29, 2026.
Key Highlights
Proposed appointment of current CEO Mr. Narsimha Shibroor Kamath as Managing Director for a 3-year tenure.
Special resolution required due to the appointee's age of 72 years as per Companies Act requirements.
E-voting period scheduled from December 31, 2025, to January 29, 2026, with results by February 2, 2026.
The appointee will hold the dual designation of Managing Director & Chief Executive Officer.
The board has appointed Mr. Vijay Yadav of AVS & Associates as the scrutinizer for the voting process.
๐ผ Action for Investors
Investors should monitor the voting results to ensure leadership continuity and review the detailed explanatory statement for specifics on the proposed remuneration package.
Bliss GVS Pharma Appoints Promoter S.N. Kamath as MD & CEO for 3-Year Term
The Board of Bliss GVS Pharma has approved the appointment of Mr. S. N. Kamath as Managing Director and CEO for a three-year term, subject to shareholder approval. Mr. Kamath, who is currently the CEO and a promoter, has been instrumental in expanding the company's global footprint to over 60 countries. The transition formalizes his leadership role as the company seeks to maintain its strategic growth trajectory. The appointment will be finalized following a Special Resolution passed via Postal Ballot.
Key Highlights
Appointment of Mr. S. N. Kamath as Managing Director for a 3-year consecutive term.
Mr. Kamath is the company promoter and has been serving as the Chief Executive Officer.
Under his leadership, the company has established a presence in more than 60 countries.
The appointment is subject to shareholder approval through a Special Resolution via Postal Ballot.
Mr. Kamath is the father of two existing Whole-Time Directors, ensuring family-led management continuity.
๐ผ Action for Investors
This move signals leadership stability and continued promoter commitment to the company's operations. Investors should monitor the Postal Ballot results and look for any new strategic initiatives under his formal MD tenure.
Bliss GVS Pharma Appoints CEO S.N. Kamath as Managing Director for 3-Year Term
The Board of Bliss GVS Pharma has approved the appointment of current CEO and promoter Mr. S.N. Kamath as the Managing Director for a period of three years. This appointment is subject to shareholder approval via a Special Resolution through a Postal Ballot. Mr. Kamath, who has been instrumental in expanding the company's presence to over 60 countries, will hold the dual title of MD & CEO. As a promoter and father to two existing Whole-Time Directors, this move ensures leadership continuity within the founding family.
Key Highlights
Mr. S.N. Kamath appointed as Managing Director for a 3-year consecutive term.
Transition from CEO to MD & CEO role pending shareholder approval via Postal Ballot.
Mr. Kamath is the company promoter and has led expansion into 60+ international markets.
Board meeting conducted on December 23, 2025, from 11:47 A.M. to 13:45 P.M.
Mr. Kamath is related to two other Whole-Time Directors, Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao.
๐ผ Action for Investors
Investors should see this as a move for leadership stability and continuity. No immediate action is required, but shareholders should participate in the upcoming Postal Ballot regarding the Special Resolution.